Persistent, recurring pain, defined as pain lasting longer
than three months, is a common health problem for up to twenty-five percent of
Americans today. Only a fraction of
these people, between thirty and fifty percent, receive adequate treatment and
relief from the therapeutics that are currently available to them. Neuropathic pain is often associated with
peripheral nerve injury often caused by compression, transection, or
inflammation. When such injured tissues
persist for extended periods of time, an ongoing excitation in primary sensory
pain neurons located in the dorsal root ganglia occur, causing chronic
pain. Recent scientific evidence has
shown that neuropathic pain occurs in part due to immune and glial cell
activation in the spinal cord and dorsal root ganglia. However, the vast majority of current pain
therapeutics target only neurons, an approach that significantly limits the
effectiveness of the treatment. Given
that, there exists a significant need for new, more effective treatment methods
for patients experiencing persistent pain.
Such a treatment should exhibit a higher effectiveness for all patients
and should be an alternative for the large fraction of patients who do not
receive sufficient pain relief from current pain therapeutic options.
at the University of New Mexico have identified a combination of novel
therapeutic compounds that play a role in the suppression of neuropathic
pain. These compounds have yielded data
that suggest a new drug target in current pain research. This technology has the capacity to develop a
revised understanding of neuroimmune signaling in response to pathological pain
as well as to identify a new class of pain therapeutics. Such therapeutics would exhibit a higher
level of effectiveness and could provide a more comprehensive pain treatment
than those currently in existence.
STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at firstname.lastname@example.org or 505-272-7886.